Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
14.68
-0.32 (-2.13%)
Dec 20, 2024, 4:00 PM EST - Market closed
Bicycle Therapeutics Employees
Bicycle Therapeutics had 284 employees as of December 31, 2023. The number of employees increased by 48 or 20.34% compared to the previous year.
Employees
284
Change (1Y)
48
Growth (1Y)
20.34%
Revenue / Employee
$129,923
Profits / Employee
-$585,479
Market Cap
1.01B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
OPKO Health | 3,930 |
Tilray Brands | 2,650 |
CareDx | 643 |
ANI Pharmaceuticals | 642 |
Rocket Pharmaceuticals | 268 |
Ardelyx | 267 |
Avadel Pharmaceuticals | 154 |
Pharvaris | 82 |
BCYC News
- 9 days ago - Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification - Business Wire
- 11 days ago - Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts - Business Wire
- 19 days ago - Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 26 days ago - Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update - Business Wire
- 5 weeks ago - Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference - Business Wire
- 6 weeks ago - Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern - Seeking Alpha
- 7 weeks ago - Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Business Wire
- 2 months ago - Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals - Business Wire